What is Actos?
Actos Warnings and Alerts
Actos Smoking Gun
Actos Lawsuits
Actos Whistleblower Lawsuit
Our Actos Attorneys
Our Case Results
Contact an Actos Lawyer

Bladder Cancer Information
Bladder Cancer Types
Bladder Cancer Symptoms
Bladder Cancer Treatment
Bladder Cancer Causes

Studies Link Actos to
Bladder Cancer

Medical Terms Dictionary

Report Adverse Side Effects
to FDA MedWatch

Report Adverse Side Effects
to Rxisk.org

Watch Our Video

Tell Us What
Happened to You

*Confirm Email
This field must be blank
*Describe your symptoms
Recent News

Actos Bladder Cancer Lawsuit Verdict Reinstated
July 16, 2015

Takeda Pharmaceuticals Continues Court Ordered Search for Missing Files in Actos Bladder Cancer Litigation
October 17, 2014
Takeda and Eli Lilly Sued Over Actos Bladder Cancer Claims
September 5, 2014

We are no longer accepting Actos cases.

Actos Bladder Cancer Lawsuits

Baum, Hedlund, Aristei & Goldman has filed Actos bladder cancer lawsuits in state and federal courts against Takeda Pharmaceuticals, accusing the drug giant of illegally marketing Actos (pioglitazone), a diabetes medication, when it knew or should have known that it was associated with an elevated risk of bladder cancer. The Actos lawsuits Baum Hedlund has filed claim that Takeda negligently failed to warn doctors and the public of this deadly risk in order to continue profiting from Actos sales.

The firm also represents whistleblower Dr. Helen Ge, a medical doctor and former safety consultant to Takeda Pharmaceuticals, who claims in her whistleblower lawsuit, that Takeda failed to report to the FDA, clinical trial adverse event data linking bladder cancer to its diabetes drug, Actos. Dr. Ge was hired by Takeda to work in the company’s pharmacovigilance department to review adverse events and to identify and evaluate potential safety signals for Actos (amongst other drugs).

According to Baum Hedlund’s Actos complaints, Takeda concealed and continues to conceal their knowledge of Actos’ unreasonably dangerous risks to the public, even after discovering scientific evidence linking Actos to a statistically significant higher risk of bladder cancer.

Our Actos lawsuits allege that Takeda willingly, wantonly and maliciously suppressed information linking Actos to an increased risk of developing bladder cancer in order to prevent any chance of its product’s registration being delayed or rejected by the FDA. We also allege that Takeda performed preclinical trials prior to FDA approval that showed early signs of a connection between Actos given to lab rats and cancerous tumors.

Takeda and Eli Lilly & Co. launched Actos (pioglitazone) jointly in 1999 and the FDA approved the drug in July of 1999 for the treatment of Type 2 diabetes. Actos belongs to a class of insulin-sensitizing drugs known as thiazolidinediones (commonly referred to as “TZD’s”).

We allege in our Actos lawsuits that Takeda knew or should have known that Actos use in humans would cause bladder cancer and that Takeda possessed pre-clinical scientific studies, including animal evidence, which signaled that bladder cancer risk needed to be further tested; all prior to Takeda applying for and obtaining approval for Actos. In fact, plaintiffs allege that Takeda has known since the early 2000’s that human clinical trials revealed Actos causes bladder cancer.

The lawsuits also allege that for over 10 years and to date, Takeda concealed and failed to completely disclose its knowledge that Actos was associated with or could cause bladder cancer or its knowledge that it had failed to fully study and test regarding that risk.

Takeda failed to update its Actos package insert to include data clearly linking Actos to bladder cancer other than an FDA required reference in the 2007 post-black box warning. Although Takeda included in the Actos package insert a reference to the 2005 study results showing that more participants taking Actos had developed bladder cancers, Takeda also inserted minimizing language stating a causal link had not been established between Actos and bladder cancer. Takeda continues to sell this potentially dangerous drug to diabetes patients at risk for bladder cancer in most countries throughout the world.

Diabetes patients interested in filing an Actos bladder cancer lawsuit against Takeda Pharmaceuticals, the manufacturer of Actos, should contact our pharmaceutical defect attorneys today. Our lawyers will help you understand your legal rights and provide aggressive representation backed by over 25 years of experience successfully handling cases from across the United States against major pharmaceutical companies.

recent study found that risk of bladder cancer is 40 percent greater in patients taking Actos for longer than two years. Takeda Pharmaceutical’s diabetes drug Actos (pioglitazone) has been linked to an increased risk of bladder cancer in numerous studies, a finding that prompted both France and Germany to suspend prescription of the popular drug. In the US, the Food and Drug Administration (FDA) has warned of this potentially life threatening Actos side effect, but has not pulled the drug off the shelves. Health Canada has also issued a warning about the increased risk of bladder cancer in diabetic patients treated with pioglitazone in particular in patients treated for the longest durations and with the highest total doses.

Our law firm is currently accepting Actos-related bladder cancer cases.

We Can Help

If you have been diagnosed with bladder cancer and you took Actos for a prolonged period of time, you may be entitled to compensation. It is imperative that you contact an experienced law firm to guide you through the complicated process of filing an Actos lawsuit.

Give us a call today at 800-827-0087 or email us so we can ensure you get the representation you and your family deserve.